The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition.
Donald W. Northfelt
No relevant relationships to disclose
Solomon I. Hamburg
No relevant relationships to disclose
Mitesh J. Borad
No relevant relationships to disclose
Mahesh Seetharam
No relevant relationships to disclose
Kelly Kevelin Curtis
No relevant relationships to disclose
Peter Lee
No relevant relationships to disclose
Brynne Crowell
Consultant or Advisory Role - Tekmira
Linda Vocila
Consultant or Advisory Role - Tekmira
Paul Fredlund
Consultant or Advisory Role - Tekmira
Mark J. Gilbert
Consultant or Advisory Role - Tekmira
Catherine Patricia Mast
No relevant relationships to disclose
Sean C. Semple
Employment or Leadership Position - Tekmira
Stock Ownership - Tekmira
Adam D. Judge
Employment or Leadership Position - Tekmira
Stock Ownership - Tekmira
Ian MacLachlan
Employment or Leadership Position - Tekmira
Stock Ownership - Tekmira
Ramesh K. Ramanathan
No relevant relationships to disclose